WEIZMANN SCIENCE PARK, NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a bio-pharmaceutical company (www.kamada.com) (the “Company”) engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, today announced that it has received an estimated NIS 2.7M from an investment made through the exercise of warrants held by GlenRock Israel. This investment was made in addition to an estimated NIS 5.0M which was invested in the last 2 months bringing GlenRock’s recent total investment through warrant exercise to an estimated NIS 7.8M.
